The term ‘triple negative breast cancer’ (TNBC) is used to classify the 10% to 20% of all breast cancers that lack estrogen receptor (ER) and progesterone receptor (PR) expression as well as amplification of the human epidermal growth factor receptor 2 (HER2)[1]. This evidence concerns the gene ERBB2 and breast carcinoma.